Insmed (INSM) Cash & Equivalents (2010 - 2026)
Insmed (INSM) posted quarterly Cash & Equivalents of $582.2 million for Q1 2026, up 44.39% year-over-year from $403.2 million in Q1 2025, and up 14.06% quarter-over-quarter from $510.4 million in Q4 2025.
Insmed (INSM) Cash & Equivalents (2010 - 2026) Analysis & Trends
Insmed's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $582.2 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 44.39% year-over-year to $582.2 million; the TTM figure through Mar 2026 stood at $582.2 million (up 44.39% YoY), while the FY2025 annual figure was $510.4 million, down 8.03% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $582.2 million, up from $510.4 million in the prior quarter.
- The five-year high for Cash & Equivalents was $1.3 billion in Q2 2025, with the low at $334.8 million in Q3 2025.
- The 5-year median for Cash & Equivalents is $515.7 million (2022), against an average of $643.9 million.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 55.18% in 2022, then soared 103.43% in 2024.
- Insmed's Cash & Equivalents stood at $1.1 billion in 2022, then slumped by 55.09% to $482.4 million in 2023, then advanced by 15.06% to $555.0 million in 2024, then slipped by 8.03% to $510.4 million in 2025, then climbed by 14.06% to $582.2 million in 2026.
- Business Quant data shows INSM's Cash & Equivalents at $582.2 million in Q1 2026, $510.4 million in Q4 2025, and $334.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 544.80 Mn |
| Mar 31, 2026 | 582.20 Mn |
| Dec 31, 2025 | 510.45 Mn |
| Sep 30, 2025 | 334.80 Mn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 403.20 Mn |
| Dec 31, 2024 | 555.03 Mn |
| Sep 30, 2024 | 461.45 Mn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 595.70 Mn |
| Dec 31, 2023 | 482.37 Mn |
| Sep 30, 2023 | 487.11 Mn |
| Jun 30, 2023 | 612.88 Mn |
| Mar 31, 2023 | 968.91 Mn |
| Dec 31, 2022 | 1.07 Bn |
| Sep 30, 2022 | 414.60 Mn |
| Jun 30, 2022 | 416.10 Mn |
| Mar 31, 2022 | 515.70 Mn |
| Dec 31, 2021 | 716.78 Mn |
| Sep 30, 2021 | 846.60 Mn |